Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ATAI
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/18/2024 | $15.00 → $10.00 | Buy | H.C. Wainwright |
4/3/2024 | $6.00 | Hold → Buy | Maxim Group |
11/1/2022 | $18.00 | Buy | Loop Capital |
11/30/2021 | $25.00 | Buy | Maxim Group |
11/22/2021 | $40.00 → $50.00 | Buy | HC Wainwright & Co. |
11/16/2021 | $25.00 → $24.00 | Outperform | Credit Suisse |
11/16/2021 | $19.00 → $17.00 | Sector Perform | RBC Capital |
11/11/2021 | $32.00 | Buy | Roth Capital |
atai Life Sciences Announces Pricing of Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, are expected to be approximately $55 mi
atai Life Sciences Announces Proposed Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering will be sold by atai. atai intends to use the net proceeds from this offering for general corporate purposes, including for working capital and to advance the clinical development of its product candi
atai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months - BPL-003 was well-tolerated with no serious or severe adverse events reported NEW YORK and BERLIN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced positive topline results from Beckley Psytech's Phase 2a open-label study of BPL-003 in 12 patients with moderate to severe alcohol use disorder (AUD). BPL-003 is a patent-protected
H.C. Wainwright reiterated coverage on atai Life Sciences N.V. with a new price target
H.C. Wainwright reiterated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $10.00 from $15.00 previously
atai Life Sciences N.V. upgraded by Maxim Group with a new price target
Maxim Group upgraded atai Life Sciences N.V. from Hold to Buy and set a new price target of $6.00
Loop Capital initiated coverage on atai Life Sciences N.V. with a new price target
Loop Capital initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $18.00
Brand Florian bought $23,120 worth of shares (20,000 units at $1.16), increasing direct ownership by 18% to 130,000 units (SEC Form 4)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 4 filed by Officer Rao Srinivas
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 3 filed by new insider Craig Kevin James
3 - ATAI Life Sciences N.V. (0001840904) (Issuer)
New insider Short Glenn Frank claimed ownership of 22,994 shares (SEC Form 3)
3 - ATAI Life Sciences N.V. (0001840904) (Issuer)
ATAI Life Sciences N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
SEC Form 424B5 filed by ATAI Life Sciences N.V.
424B5 - ATAI Life Sciences N.V. (0001840904) (Filer)
SEC Form 424B5 filed by ATAI Life Sciences N.V.
424B5 - ATAI Life Sciences N.V. (0001840904) (Filer)
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials – Eight new programs added to platform since January 2021 bringing total, as of today, to 13 discovery and drug development programs and four enabling technologies – Ended 2021 very well capitalized with $362 million to execute our strategy to achieve clinically meaningful and sustai
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update. To access the webcast, please log in at https://wsw.com/webcast/cc/atai/1358298. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. About atai Life Sciences atai was founded in 2018 as a response to the significant
Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)